AGRX — Agile Therapeutics Share Price
0.000.00%
Last trade - 00:00- $10.43m
- $7.58m
- $19.59m
- 48
- 46
- 70
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 1.53 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.48 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -62.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.75 | 4.1 | 10.88 | 19.59 | 36.84 | 50.93 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +41.03 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
Directors
- Alfred Altomari CHM (62)
- Dennis Reilly CFO (62)
- Geoffrey Gilmore SVP (55)
- Robert Conway SVP (64)
- Paul Korner SVP (55)
- Seth Fischer LED (65)
- Josephine Torrente DRC
- Sharon Barbari IND (66)
- Sandra Carson IND (67)
- John Hubbard IND (64)
- Ajit Shetty IND (75)
- James Tursi IND (55)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 5th, 1997
- Public Since
- May 22nd, 2014
- No. of Shareholders
- 13
- No. of Employees
- 19
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 6,904,498
- Address
- 500 College Road East, Suite 310, PRINCETON, 08540-6635
- Web
- https://www.agiletherapeutics.com/
- Phone
- +1 6096831880
- Auditors
- Ernst & Young LLP
Upcoming Events for AGRX
Similar to AGRX
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Agile Therapeutics share price?
As of Today at 19:07 UTC, shares in Agile Therapeutics are trading at $1.51. This share price information is delayed by 15 minutes.
How has the Agile Therapeutics share price performed this year?
Shares in Agile Therapeutics last closed at $1.51 and the price had moved by -27.4% over the past 365 days. In terms of relative price strength the Agile Therapeutics share price has underperformed the S&P500 Index by -40.44% over the past year.
What are the analyst and broker recommendations for Agile Therapeutics?
The overall consensus recommendation for Agile Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Agile Therapeutics dividend yield?
Agile Therapeutics does not currently pay a dividend.
Does Agile Therapeutics pay a dividend?
Agile Therapeutics does not currently pay a dividend.
When does Agile Therapeutics next pay dividends?
Agile Therapeutics does not currently pay a dividend.
How do I buy Agile Therapeutics shares?
To buy shares in Agile Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Agile Therapeutics?
As of the previous close price of $1.51, shares in Agile Therapeutics had a market capitalisation of $10.43m.
Where are Agile Therapeutics shares listed?
Here are the trading details for Agile Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: AGRX
What kind of share is Agile Therapeutics?
Based on an overall assessment of its quality, value and momentum Agile Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Agile Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Agile Therapeutics is $5.00. That is 231.13% above the last closing price of $1.51.
Analysts covering Agile Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $0.78 for the next financial year.
Find out moreWhat is the trend in the Agile Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Agile Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +57.07%.
As of the last closing price of $1.51, shares in Agile Therapeutics were trading +31.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Agile Therapeutics PE Ratio?
The Agile Therapeutics PE ratio based on its reported earnings over the past 12 months is 1.53. The shares last closed at $1.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Agile Therapeutics?
Agile Therapeutics' management team is headed by:
- Alfred Altomari - CHM
- Dennis Reilly - CFO
- Geoffrey Gilmore - SVP
- Robert Conway - SVP
- Paul Korner - SVP
- Seth Fischer - LED
- Josephine Torrente - DRC
- Sharon Barbari - IND
- Sandra Carson - IND
- John Hubbard - IND
- Ajit Shetty - IND
- James Tursi - IND